The Monaco Energy Boat Challenge enters a new era with AI on board
'This year there is more people, more boats, more involvement of the industry. Plus, we have a new category, a new Class named AI. Not only Artificial intelligence, but also having some boats that are representing the drone industry, the boat can do some maneuvers themselves, they can dock themselves, they can go for missions themselves, so something very new. And after there is plenty of innovation,' explained Jeremie Lagarrigue president of the Jury Committee. 'We have AI directly integrated into the battery management system in order to optimize the management of energy on board. We have also a new internal combustion engine running on hydrogen that might be a good option for the yacht industry on retrofit and more and more hydrogen with fuel cell technology involving, having a less weight, better performance and starting to be more and more competitive with the battery technology,' added Lagarrigue.
Divided into four categories, teams explore technologies for yachting's future: AI Class where the focus is on autonomous boats piloted by artificial intelligence; Energy Class which tests technologies aboard standardised hulls; SeaLab Class, floating laboratories of experimentation with focus this year on pioneering hydrogen technologies; Open Sea Class which showcases CE-certified zero-emission prototypes up to 25m that can take at least 3 people. Of all projects competing, 30 boats are powered by electricity, 12 operate on hydrogen and 12 prototypes will be on foils.
The big news is the Artificial Intelligence debut on board. In the AI Class, the Polish from AGH Solar Boat are combining LiDAR, 3D cameras and use of advanced AI algorithms running on a Jetson Orion computer. The Hungarian team, BME Solar Boat Team, features a lightweight solar electric racing boat, optimised for autonomous navigation, powered by advanced electric propulsion systems and onboard AI-driven electronics. 'The main focus of the AI class is to develop and implement autonomous boats that have to complete full autonomous tasks using different type of technology, sensor and AI techniques. The introduction of AI this year is very important because it helps to push the technology to its boundaries and it helps to facilitate the introduction of innovation in all of sectors,' said Maria Marcello, who is on the AI Technical Committee. In the Energy Class, Sambuk Racing from Qatar University make their first appearance and will be using a solid-state lithiun battery, the first of this kind of technology in the history of the Challenge. In the SeaLab Class, from Scotland, Heriot-Watt University has integrated a solid-state hydrogen storage system, safer and more compact. In addition, Plus Zero will be testing a hydrogen internal combustion engine for the first time in the Challenge. Besides that, they use solid state hydrogen storage which uses chemical reaction with water to release hydrogen.
For more information:
Press Office LaPresse -
ufficio.stampa@lapresse.it
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4bc0b69e-1315-4569-a436-895a5ee02361
A video accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a972b483-ba8c-4bef-bd32-8317d64e6743
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions. Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@ and postsalemanualrequests@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi WaarichSenior Director, Investor
Business Upturn
3 hours ago
- Business Upturn
ROHM Develops an Ultra-Compact MOSFET Featuring Industry-Leading* Low ON-Resistance Ideal for Fast Charging Applications
Santa Clara, CA and Kyoto, Japan, July 08, 2025 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced the development of the AW2K21, a 30V N-channel MOSFET in a common-source configuration that delivers an industry-leading ON-resistance of just 2.0mΩ (typ.) in a compact 2.0mm × 2.0mm package. With the rise of compact devices featuring large-capacity batteries, such as smartphones, the need for fast charging functionality to shorten charging times continues to grow. These applications require bidirectional protection to prevent reverse current flow to peripheral ICs and other components when not actively supplying or receiving power. What's more, fast charging involves high current power transfer, leading smartphone manufacturers to demand stringent specifications for MOSFETs, including a maximum current rating of 20A, breakdown voltage between 28V and 30V, and an ON-resistance of 5mΩ or less. However, meeting these requirements with standard solutions typically necessitates the use of two large low ON-resistance MOSFETs, increasing board space along with mounting complexity. In response, ROHM developed an ultra-compact low ON-resistance MOSFET optimized for fast high-power charging. The AW2K21 adopts a proprietary structure that enhances cell density while minimizing the ON-resistance per unit chip area. Two MOSFETs are integrated into a single package, allowing a single part to support bidirectional protection applications (commonly required in power supply and charging circuits). The proprietary structure also places the drain terminal on the top surface, unlike on the backside in standard vertical trench MOS structures. This enables the use of a WLCSP, which achieves a larger chip-to-package area ratio that further reduces ON-resistance per unit area. As a result, the new product not only minimizes power loss but also supports high current operation, making it ideal for high-power fast charging applications despite its ultra-compact size. For example, in power supply and charging circuits for compact devices, standard solutions typically require two 3.3mm × 3.3mm MOSFETs. In contrast, the AW2K21 can achieve the same functionality with a single 2.0mm × 2.0mm unit, reducing the footprint and ON-resistance by approximately 81% and 33%, respectively. Even compared to similarly sized GaN HEMTs, ON-resistance is decreased by up to 50%, contributing to lower power consumption and increased space savings across a variety of applications. The AW2K21 is also suitable for use as a unidirectional protection MOSFET in load switch applications, where it maintains the industry's lowest ON-resistance. At the same time, ROHM is further pushing the limits of miniaturization with the development of an even smaller 1.2mm × 1.2mm model. Going forward, ROHM remains dedicated to supporting the miniaturization and energy efficiency of electronic systems through compact, high-performance solutions that contribute to the realization of a sustainable society. Online Sales Information Sales Launch Date: April 2025 Online Distributors: DigiKey™, Mouser™ and Farnell™ Applicable Part No: AW2K21 The product will be offered at other online distributors as it becomes available. Note: DigiKey™, Mouser™ and Farnell™ are trademarks or registered trademarks of their respective companies. _______________________________________________________________________________________________________________________________________ *ROHM July 2025 study Attachments ROHM Develops the AW2K21, a 30V N-Channel MOSFET Comparison Between Standard Products and ROHM's New Product the AW2K21 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
3 hours ago
- Business Upturn
Zig-Zag Launches New Premium Natural Leaf Cigar Line – Zig-Zag Woods
By GlobeNewswire Published on July 9, 2025, 02:53 IST Los Angeles, California, July 08, 2025 (GLOBE NEWSWIRE) — Zig-Zag Launches New Premium Natural Leaf Cigar Line – Zig-Zag Woods Slow-Burning, Boldly Flavored, and Value-Priced for High Turnover in Convenience and Smoke Shop Channels Zig-Zag, a heritage brand trusted by millions, proudly announces the launch of Zig-Zag Woods, a new line of premium natural leaf cigars crafted for today's adult cigar consumer and strategically designed for convenience stores and smoke shops. With more than 58% of consumers referring to rough-cut cigars as 'woods', this launch meets consumer expectations with a name and format that resonates. Zig-Zag Woods features a slow-burning, all-natural leaf wrap filled with premium rough-cut tobacco, delivering a rich and smooth smoking experience. With bold flavor profiles and recognizable Zig-Zag branding, this line is engineered for fast sell-through and high margins. Over 300 million rough-cut cigars are sold annually (MSA), demonstrating the strength of this segment, and Zig-Zag Woods is primed to compete and win. Product Offering: 5 Varieties: Natural Silk & Berries Sweet Aromatic Crème Royale Velvet Pre-Priced: $1.39 for 2 cigars $1.39 for 2 cigars Packaging Configuration: 15 pouches per carton 24 cartons per case Whether your customers prefer the boldness of Sweet Aromatic or the smoothness of Velvet, Zig-Zag Woods provides a flavor for every taste. With its competitive price point, premium quality, and shelf-ready format, Zig-Zag Woods is primed to become a top seller in the natural leaf cigar segment. 'Customers have been asking for a premium value-added product that moves quickly and satisfies customers. Zig-Zag Woods is our answer,' said Jessica Chesney, SBM of Marketing at Zig-Zag. 'We've combined quality, flavor variety, and value into a package that's a win for both consumers and the trade.' Now Shipping Nationwide Zig-Zag Woods are now available for wholesale and retail ordering. For more information, promotional assets, or to place an order, contact Zig-Zag customer service at (800) 331-5962 [email protected] or visit TPB Marketplace. About Zig-Zag Zig-Zag is a market leader in premium tobacco and smoking accessories, known for its authenticity, innovation, and quality. With a legacy spanning over 140 years, Zig-Zag continues to evolve with consumer trends while delivering reliable products to its retail partners. Zig-Zag is exclusively distributed by Turning Point Brands (NYSE: TPB), a manufacturer, marketer, and distributor of branded consumer products. Attachment Zig-Zag Launches New Premium Natural Leaf Cigar Line – Zig-Zag Woods Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
